Trials (Léon Bérard Center) - Revision history

Francine at 18:34, 14 December 2025

2025-12-14T18:34:52Z

← Older revision		Revision as of 18:34, 14 December 2025
Line 4:		Line 4:
	<span style="display:none">francecountry</span>		<span style="display:none">francecountry</span>
	Go back to [[Léon Bérard Center]] page		Go back to [[Léon Bérard Center]] page

			=== Trials: How to participate ===
			'''Contact information:''' [https://www.centreleonberard.fr/professionnel-de-sante-chercheur/recherche-contre-le-cancer/la-recherche-clinique-au-centre-leon-berard Click here to access].


	'''NCTID''': NCT01222767		'''NCTID''': NCT01222767
Line 1,459:		Line 1,463:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:41:57Z

Update categories.

← Older revision		Revision as of 12:41, 6 December 2025
Line 1,438:		Line 1,438:
	<span style="display:none">hasTrialTitle::DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)</span>		<span style="display:none">hasTrialTitle::DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)</span>
	<span style="display:none">hasTrialTitle::Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)</span>		<span style="display:none">hasTrialTitle::Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)</span>
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Francine at 20:42, 2 December 2025

2025-12-02T20:42:54Z

← Older revision		Revision as of 20:42, 2 December 2025
Line 2:		Line 2:
	<span style="display:none">forproviders</span>		<span style="display:none">forproviders</span>
	<span style="display:none">forresearchers</span>		<span style="display:none">forresearchers</span>
	<span style="display:none">~~france~~</span>		<span style="display:none">francecountry</span>
	Go back to [[Léon Bérard Center]] page		Go back to [[Léon Bérard Center]] page

Lucas: Update categories.

2025-12-02T13:59:57Z

Update categories.

Show changes

Victor at 15:53, 6 November 2024

2024-11-06T15:53:39Z

← Older revision		Revision as of 15:53, 6 November 2024
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
			{{france}}
	Go back to [[Léon Bérard Center]] page		Go back to [[Léon Bérard Center]] page

Francine at 16:26, 4 January 2024

2024-01-04T16:26:26Z

← Older revision		Revision as of 16:26, 4 January 2024
Line 345:		Line 345:
	'''Condition''': Indolent Non-Hodgkin’s Lymphomas		'''Condition''': Indolent Non-Hodgkin’s Lymphomas
	'''NCTID''': NCT03456063		'''NCTID''': NCT03456063
	'''Title''': [[hasTrialTitle::A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)]]		'''Title''': [[hasTrialTitle::A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) ]]
	'''Study Summary''': This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.		'''Study Summary''': This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.
	'''Sponsor''': Hoffmann-La Roche		'''Sponsor''': Hoffmann-La Roche
Line 365:		Line 365:
	'''Condition''': Carcinoma, Transitional Cell		'''Condition''': Carcinoma, Transitional Cell
	'''NCTID''': NCT01846416		'''NCTID''': NCT01846416
	'''Title''': [[hasTrialTitle::A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]]]		'''Title''': [[hasTrialTitle::A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] ]]
	'''Study Summary''': This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression. Eligible participants will be categorized in to three groups as follows: # Participants with no prior chemotherapy for advanced disease; # Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants); # Participants who are 2L+ and previously treated for brain metastases.		'''Study Summary''': This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression. Eligible participants will be categorized in to three groups as follows: # Participants with no prior chemotherapy for advanced disease; # Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants); # Participants who are 2L+ and previously treated for brain metastases.
	'''Sponsor''': Genentech, Inc.		'''Sponsor''': Genentech, Inc.

Francine at 16:20, 4 January 2024

2024-01-04T16:20:48Z

← Older revision		Revision as of 16:20, 4 January 2024
Line 95:		Line 95:
	'''Condition''': Non-small Cell Lung Cancer		'''Condition''': Non-small Cell Lung Cancer
	'''NCTID''': NCT01322490		'''NCTID''': NCT01322490
	'''Title''': A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer		'''Title''': [[hasTrialTitle::A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer]]
	'''Study Summary''': The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.		'''Study Summary''': The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.
	'''Sponsor''': Bavarian Nordic		'''Sponsor''': Bavarian Nordic

Francine at 16:20, 4 January 2024

2024-01-04T16:20:08Z

← Older revision		Revision as of 16:20, 4 January 2024
Line 15:		Line 15:
	'''Condition''': Ewing’s Sarcoma		'''Condition''': Ewing’s Sarcoma
	'''NCTID''': NCT01798485		'''NCTID''': NCT01798485
	'''Title''': A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC		'''Title''': [[hasTrialTitle::A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC]]
	'''Study Summary''': The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.		'''Study Summary''': The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.
	'''Sponsor''': Synta Pharmaceuticals Corp.		'''Sponsor''': Synta Pharmaceuticals Corp.

Francine at 16:19, 4 January 2024

2024-01-04T16:19:19Z

Show changes

Francine: Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Léon Bérard Center page '''NCTID''': NCT01222767 '''Title''': Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy '''Study Summary''': This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Loc..."

2023-12-01T21:52:05Z

Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Léon Bérard Center page '''NCTID''': NCT01222767 '''Title''': Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy '''Study Summary''': This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Loc..."

Show changes